ReviewFrontiers in cellular and infection microbiology2026
Point-of-care molecular diagnostics and drug-resistance mechanisms in neglected infectious diseases: current advances and future therapeutic opportunities.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Antibiotic Resistance and the Return to a Pre-Antibiotic Era: A Critical Narrative Review of a Global Catastrophe.Biomedicines · 2026Review
- Operational Validity in Decentralized Molecular Point-of-Care Diagnostics: A Human Factors Engineering Perspective.Diagnostics (Basel, Switzerland) · 2026Review
- Improving the Precision of Etiological Diagnosis in Bacterial Infections Using Molecular Technologies: A Comparative Analysis of Platforms, AI Integration, and Point-of-Care Deployment.International journal of molecular sciences · 2026Review
- Molecular insights into antimicrobial resistance in human bacterial pathogens: mechanisms, resistance genes, and translational diagnostic applications.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising burden of neglected infectious diseases and the accelerating spread of antimicrobial resistance (AMR) demand rapid, accurate, and decentralized diagnostic solutions. Point-of-care (POC) molecular diagnostics enable early diagnosis and resistance profiling during the clinical encounter, without reliance on centralized laboratories, which is particularly important in low-resource settings. Molecular POC technologies are being developed around the following advances: isothermal nucleic acid amplification technologies, rapid polymerase chain reaction (PCR), CRISPR-based diagnostic detection technologies, nanomaterials-enabled biosensors, and microfluidic platforms for sample-to-results with near laboratory-quality accuracy within clinically relevant timeframes (typically < 30 minutes). The combination of artificial intelligence (AI) and cloud-based digital health systems supports the automated interpretation and provision of real-time surveillance and antimicrobial stewardship. Next-generation molecular POC platforms provide higher sensitivity and mechanistic insights into drug-resistance in TB, malaria, and bacterial infections. Barriers include clinical validation, cost, scalability, and equitable access. The convergence of molecular diagnostics, nanotechnology and AI-powered analytics leads to future-oriented, transformative opportunities in precision therapy areas, AMR surveillance and infectious disease preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.